Emerging Drug Developer: Immune Design
Boom times in the vaccine industry have helped breed a new generation of vaccine development start-ups, and Seattle-based Immune Design believes it can be one of the most successful. The biotech company combines research undertaken by Steven Reed on small molecules and the viral vector work of Nobel laureate David Baltimore in a company that is advancing a new approach to adjuvants and vaccines.
And as we see in so many biotech start-ups, a venture capital player helped put it all together. Article
Be the first to comment
More stories about Emerging Drug Developer
Comments
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
